Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a …
Over the last 12 months, insiders at Aptevo Therapeutics Inc. have bought $0 and sold $0 worth of Aptevo Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Aptevo Therapeutics Inc. have bought $49.69M and sold $16.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 348,554 shares for transaction amount of $7.92M was made by TANG KEVIN C (10 percent owner) on 2020‑11‑06.
2021-11-23 | Sale | TANG KEVIN C | 921,336 12.987% | $11.25 | $10.37M | -73.69% | ||
2021-11-22 | Sale | TANG KEVIN C | 10 percent owner | 255,331 5.9122% | $7.03 | $1.8M | -30.86% | |
2021-11-19 | Sale | TANG KEVIN C | 10 percent owner | 213,800 4.7422% | $7.59 | $1.62M | -38.63% | |
2021-11-18 | Sale | TANG KEVIN C | 10 percent owner | 369,533 8.1153% | $8.34 | $3.08M | -44.69% | |
2020-11-06 | TANG KEVIN C | 10 percent owner | 348,554 7.5668% | $22.73 | $7.92M | +8.23% | ||
2020-11-05 | TANG KEVIN C | 10 percent owner | 1.25M 25.0765% | $18.78 | $23.5M | +20.82% | ||
2020-11-04 | TANG KEVIN C | 10 percent owner | 1.27M 24.3464% | $14.34 | $18.27M | +50.91% | ||
2019-08-16 | Maddux Randy Joe | SVP Operations, CMO | 50,000 0.1097% | $0.76 | $38,000 | -25.67% | ||
2019-08-12 | El-Hibri Fuad | director | 200,000 0.4342% | $0.76 | $151,040 | -25.24% | ||
2019-07-29 | El-Hibri Fuad | Board of Directors | 110,030 0.2409% | $0.83 | $91,721 | -31.45% | ||
2019-07-23 | El-Hibri Fuad | Board of Directors | 20,000 0.0452% | $0.90 | $17,992 | -34.35% | ||
2019-07-22 | El-Hibri Fuad | Board of Directors | 60,000 0.1331% | $0.89 | $53,202 | -34.06% | ||
2019-07-19 | El-Hibri Fuad | Board of Directors | 52,920 0.1212% | $0.90 | $47,480 | -33.33% | ||
2019-07-18 | El-Hibri Fuad | Board of Directors | 28,808 0.0638% | $0.87 | $25,193 | -33.40% | ||
2019-07-17 | El-Hibri Fuad | Board of Directors | 38,272 0.085% | $0.87 | $33,408 | -32.68% | ||
2019-07-16 | El-Hibri Fuad | Board of Directors | 22,750 0.0486% | $0.85 | $19,324 | -33.41% | ||
2019-07-11 | El-Hibri Fuad | Board of Directors | 29,382 0.0649% | $0.85 | $24,907 | -30.51% | ||
2019-07-10 | El-Hibri Fuad | director | 37,838 0.0843% | $0.85 | $32,117 | -30.01% | ||
2019-06-25 | Abdun-Nabi Daniel | Board of Directors | 33,334 0.0753% | $0.90 | $30,001 | -33.16% | ||
2019-06-14 | White Marvin L | President and CEO | 100,000 0.2219% | $0.88 | $88,000 | -30.63% |
Increased Positions | 11 | +64.71% | 45,930 | +132.41% |
Decreased Positions | 8 | -47.06% | 32,082 | -92.49% |
New Positions | 4 | New | 4,969 | New |
Sold Out Positions | 8 | Sold Out | 32,082 | Sold Out |
Total Postitions | 20 | +17.65% | 48,535 | +39.92% |
Virtu Financial Llc | $83.00 | 2.16% | 21,627 | +20,493 | +1,807.14% | 2024-12-31 |
Hrt Financial Lp | $47.00 | 1.23% | 12,324 | +11,564 | +1,521.58% | 2024-12-31 |
Jpmorgan Chase & Co | $17.00 | 0.45% | 4,529 | +4,528 | +452,800% | 2024-12-31 |
Diadema Partners Lp | $15.00 | 0.41% | 4,050 | +4,050 | New | 2024-12-31 |
Morgan Stanley | $15.00 | 0.39% | 3,927 | +3,922 | +78,440% | 2024-12-31 |
Tower Research Capital Llc (Trc) | $4.00 | 0.11% | 1,086 | +408 | +60.18% | 2024-12-31 |
Ubs Group Ag | $3.00 | 0.08% | 783 | +783 | New | 2024-12-31 |
Sbi Securities Co., Ltd. | $1.00 | 0.01% | 131 | +131 | New | 2024-12-31 |
Osaic Holdings, Inc. | $0 | 0.01% | 45 | +44 | +4,400% | 2024-12-31 |
Blackrock, Inc. | $0 | <0.01% | 24 | 0 | 0% | 2024-12-31 |